These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32036006)

  • 21. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice.
    Lourenco LM; Jiang Y; Drobnitzky N; Green M; Cahill F; Patel A; Shanneik Y; Moore J; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):767-775. PubMed ID: 29413287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
    Barreto-Andrade JC; Efimova EV; Mauceri HJ; Beckett MA; Sutton HG; Darga TE; Vokes EE; Posner MC; Kron SJ; Weichselbaum RR
    Mol Cancer Ther; 2011 Jul; 10(7):1185-93. PubMed ID: 21571912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
    Hastak K; Bhutra S; Parry R; Ford JM
    Oncotarget; 2017 Apr; 8(16):26344-26355. PubMed ID: 28412751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
    Bhute VJ; Ma Y; Bao X; Palecek SP
    Sci Rep; 2016 Nov; 6():36061. PubMed ID: 27811964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
    Schaefer NG; James E; Wahl RL
    Nucl Med Commun; 2011 Nov; 32(11):1046-51. PubMed ID: 21956491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
    Lee TW; Wong WW; Dickson BD; Lipert B; Cheng GJ; Hunter FW; Hay MP; Wilson WR
    Int J Radiat Biol; 2019 Dec; 95(12):1597-1612. PubMed ID: 31490091
    [No Abstract]   [Full Text] [Related]  

  • 32. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
    Xue C; Xu Y; Ye W; Xie Q; Gao H; Xu B; Zhang D; Jiang J
    Gynecol Oncol; 2020 Apr; 157(1):222-233. PubMed ID: 31987601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.
    Mariano G; Ricciardi MR; Trisciuoglio D; Zampieri M; Ciccarone F; Guastafierro T; Calabrese R; Valentini E; Tafuri A; Del Bufalo D; Caiafa P; Reale A
    Oncotarget; 2015 Jun; 6(17):15008-21. PubMed ID: 25938539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
    Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
    Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 38. PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.
    Guillot C; Favaudon V; Herceg Z; Sagne C; Sauvaigo S; Merle P; Hall J; Chemin I
    BMC Cancer; 2014 Aug; 14():603. PubMed ID: 25139788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?
    Césaire M; Thariat J; Candéias SM; Stefan D; Saintigny Y; Chevalier F
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30487462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.
    Efimova EV; Mauceri HJ; Golden DW; Labay E; Bindokas VP; Darga TE; Chakraborty C; Barreto-Andrade JC; Crawley C; Sutton HG; Kron SJ; Weichselbaum RR
    Cancer Res; 2010 Aug; 70(15):6277-82. PubMed ID: 20610628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.